ABSTRACT
Background A rare and fatal disease resembling mucopolysaccharidosis in infants, is caused by impaired intracellular endocytic trafficking due to deficiency of core components of the intracellular membrane-tethering protein complexes, HOPS and CORVET.
Methods Whole Exome Sequencing identified a novel VPS33A mutation in a patient suffering from a variant form of mucopolysaccharidosis. Electron and confocal microscopy, immunoblotting, and glycosphingolipid trafficking experiments were undertaken to investigate the effects of the mutant VPS33A in patient-derived skin fibroblasts.
Results We describe an attenuated juvenile form of VPS33A-related syndrome - mucopolysaccharidosis plus in a man who is homozygous for a hitherto unknown missense mutation (NM_022916.4: c.599 G>C; R200P) in a conserved region of the VPS33A gene. Urinary glycosaminoglycan analysis revealed increased heparan, dermatan sulphates and hyaluronic acid. We showed decreased abundance of VPS33A in patient derived fibroblasts and provided evidence that the R200P mutation leads to destabilisation of the protein and proteasomal degradation. As in the infantile form of mucopolysaccharidosis plus, the endocytic compartment in the fibroblasts also expanded – a phenomenon accompanied by increased endolysosomal acidification and impaired intracellular glycosphingolipid trafficking. Experimental treatment of the patient’s cultured fibroblasts with the proteasome inhibitor, bortezomib, or exposure to an inhibitor of glucosylceramide synthesis, eliglustat, improved glycosphingolipid trafficking.
Conclusion To our knowledge this is the first report of an attenuated juvenile form of VPS33A insufficiency characterised by appreciable residual endosomal-lysosomal trafficking and a milder mucopolysaccharidosis plus than the disease in infants. Our findings expand the proof of concept of redeploying clinically approved drugs for therapeutic exploitation in patients with juvenile as well as infantile forms of mucopolysaccharidosis plus disease.
Competing Interest Statement
E.V.P: travel expenses - Global Challenge Research Grant, Research England GCRF (Inst); attendance and travel expenses to 2019 ESGLD Workshop, ESGLD. H.J.C.: virtual attendance to WORLD Symposium 2022, sponsored by Sanofi. T.M.C.: honoraria for lectures and programme planning and support for unrelated investigator sponsored research from Takeda and Sanofi Aventis. The other authors declare no competing interests.
Funding Statement
This work was supported by Global Challenge Research Grant, Research England GCRF [QR AY2019-20; E.V.P.]; Metabolic Theme of the Cambridge Biomedical Research Centre supported by the National Institute of Health Research, UK [BRC-1215-20014; T.M.C. and E.V.P.]; Medical Research Council research grant [MR/R009015/1; J.P.L. and N.A.B.] and the European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement [No. 101030247; P.T.M.]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study in the present case patient P6 was approved by the Ethics Committee of The Institute of Medical Genetics, Wolfson Medical Centre, Israel. Parents of the patient consented for publication. Informed consent was obtained from the parents of the patients in accordance with the standards of the Declaration of Helsinki. The patient P7 was referred for diagnostic advice, the urine sample was obtained with patient consent for clinical investigation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data relevant to the study are included in the article or uploaded as supplementary information. Data are available upon reasonable request.
